Biogen, headquartered in Cambridge, Massachusetts, specializes in therapies for neurological diseases, employing 7,570 people and offering treatments for conditions like MS, SMA, Alzheimer's, and ALS. Their product portfolio includes TECFIDERA, SPINRAZA, and collaborations on LEQEMBI and others.
Biogen (BIIB) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Biogen's actual EPS was $3.02, beating the estimate of $2.58 per share, resulting in a 17.28% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
